Follow The Filings

MYGN Myriad Genetics Inc.

Health Care, filed as MYRIAD GENETICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 exit

In 2026 Q2 Glenview Capital Management sold out of Myriad Genetics.

Who owns MYGN

Sorted by value, long equity only, as of 2026 Q2.

History
Glenview Capital Management exited 2026 Q2 Last 2026 Q1 0.61% Exit −0.61% 5,411,978 $24M History

0 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by MYGN's executives, directors and 10% owners in the last 12 months, from their Form 4s

All MYGN insider trades
  • $722K bought by 3 insiders
  • None no sales outside a trading plan
  • $67K sold by 1 insider under 10b5-1 plans
  1. Rashmi Kumar Director
    Planned sale
    $67K 15,000 shares at $4.46 8% of stake
    Traded Jun 8 Filed Jun 9
    ↗
  2. Paul Bisaro Director
    Buy
    $28K 7,500 shares at $3.69 +8.3% to stake
    Traded May 14 Filed May 14
    ↗
  3. Samraat S. Raha CEO
    Buy
    $200K 40,000 shares at $5.00 +8.8% to stake
    Traded Mar 9 Filed Mar 9
    ↗
  4. S. Louise Phanstiel Director
    Buy
    $495K 104,507 shares at $4.73 +59% to stake
    Traded Feb 25–27 Filed Feb 27
    ↗

Also filed in the last 12 months, not counted as buying or selling: 34 share withholdings for taxes and 23 stock grants.

SEC filings

Recent issuer filings from EDGAR, 18 shown.

Filed Form Detail Links
8-K 1.01,7.01,9.01 Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02 Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 3 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $753.2M $837.6M $824.5M
Gross profit — $585.4M $576.6M
Gross margin * — 69.9% 69.9%
Net income -$263.3M -$127.3M -$365.9M
Net margin * -35.0% -15.2% -44.4%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $313.6M $298M $332.6M
Total non-current assets * $832.9M $729.6M $374M
Total assets $1.15B $1.03B $0.707B
Total current liabilities $155.9M $164.1M $133.8M
Total non-current liabilities * $207.4M $162.4M $204.8M
Total equity $783.2M $701.1M $368M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$110.9M -$8.7M $1.8M
Cash from investing $31.9M -$11.9M -$27.4M
Cash from financing $152.9M -$7.4M $64.2M
Net change in cash $74.5M -$29M $39.4M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.